A new category of psychotropic drugs: neuroactive lipids as exemplified by ethyl eicosapentaenoate (E-E)
by
Horrobin DF.
Laxdale Ltd., Kings Park House,
Laurelhill Business Park, Stirling, FK7 9JQ Scotland.
agreen@laxdale.co.uk
Prog Drug Res 2002;59:171-99

ABSTRACT

New treatments for psychiatric disorders are urgently required. Recent reviews show that there have been no improvements in efficacy of drugs for either affective disorders or schizophrenia since the first compounds were introduced over 40 years ago. Neuroactive lipids represent an entirely novel class of psychotropic compounds. Ethyl eicosapentaenoate is the first example of this group. Placebo-controlled studies have found it to be effective in depression, in treatment-unresponsive schizophrenia and in tardive dyskinesia. It is extremely well tolerated with none of the usual side-effects of either antidepressants or neuroleptics. It probably works by modulating postreceptor signal transduction processes.

EPA
DHA
SAMe
Dopamine
Low-fat blues
Food and mood
Omega 3 fatty acids
PUFAs for pain-relief
Folate and vitamin B12
Mood, food and cognition
Omega 3 fatty acids in bipolar disorder
Omega-3 for borderline personality disorder
Omega-3, inflammation/autoimmune diseases
Ethyl-eicosapentaenoate as an antidepressant

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family